← FDA DRUG APPROVALS

FDA ANDA · ANDA090547

VORICONAZOLE

Sponsor: MYLAN PHARMS INC

APPLICATION
ANDA090547
TYPE
ANDA
ORIGINAL APPROVAL
2010-04-22
LATEST ACTION
2025-10-23
ROUTE
ORAL
DOSAGE FORM
TABLET
MARKETING STATUS
Prescription

Products

VORICONAZOLEPrescription
VORICONAZOLE 200MG · TABLET · ORAL
VORICONAZOLEPrescription
VORICONAZOLE 50MG · TABLET · ORAL

Approval history

2025-10-23Labeling · Supplement 19 · standardAP
2023-09-11Labeling · Supplement 9 · standardAP
2023-09-11Labeling · Supplement 15 · standardAP
2023-09-11Labeling · Supplement 13 · standardAP
2023-09-11Labeling · Supplement 11 · standardAP
2023-09-11Labeling · Supplement 8 · standardAP
2023-09-11Labeling · Supplement 18 · standardAP
2023-09-11Labeling · Supplement 16 · standardAP
2023-09-11Labeling · Supplement 12 · standardAP
2023-09-11Labeling · Supplement 10 · standardAP
2016-01-12Labeling · Supplement 5 · standardAP
2016-01-12Labeling · Supplement 6 · standardAP
2013-03-27Labeling · Supplement 2AP
2011-03-09Labeling · Supplement 1AP
2010-04-22OriginalLetterAP
VIEW ON DRUGS@FDA ↗

Related on SPEQ

Pharma industryGMP disciplineFDA drug shortagesFDA enforcement & recalls

Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →